News
NAGE
3.255
+0.77%
0.025
Niagen Bioscience announces publication on muscle epigenetic age
TipRanks · 2h ago
Aging Cell Publishes Study In 'Aging Cell' Showing Niagen NR Supplementation Reduces Muscle Biological Aging and Supports Healthy Muscle Function
Benzinga · 2h ago
Niagen Bioscience reports analysis finds Niagen NR cuts muscle epigenetic age by about 2.5 years in 5-month trial
PUBT · 2h ago
Niagen Bioscience (NAGE) Gets a Buy from Roth MKM
TipRanks · 1d ago
Niagen Bioscience CEO to speak at Canaccord Genuity Growth Conference
PUBT · 1d ago
Weekly Report: what happened at NAGE last week (0720-0724)?
Weekly Report · 1d ago
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
Barchart · 1d ago
Niagen Bioscience schedules Q2 earnings call after market close
PUBT · 07/21 12:32
Press Release: Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Dow Jones · 07/21 12:32
Niagen Bioscience price target lowered to $11 from $12 at Ladenburg
TipRanks · 07/21 12:00
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
NASDAQ · 07/21 11:05
Weekly Report: what happened at NAGE last week (0713-0717)?
Weekly Report · 07/20 09:19
Niagen Bioscience names Abhijit Kale senior director of global external research
PUBT · 07/16 12:37
NIAGEN BIOSCIENCE APPOINTS ABHIJIT KALE, PH.D., AS SENIOR DIRECTOR OF GLOBAL EXTERNAL RESEARCH
Reuters · 07/16 12:32
Niagen Bioscience wins FDA rare pediatric disease designation for NB4168 in ataxia telangiectasia
PUBT · 07/13 13:19
BUZZ-Niagen rises after U.S., EU rare disease designations for drug candidate
Reuters · 07/13 12:49
Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168
TipRanks · 07/13 12:35
Niagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia Telangiectasia
Benzinga · 07/13 12:34
NIAGEN BIOSCIENCE RECEIVES EXCLUSIVE U.S. FDA RARE PEDIATRIC DISEASE (RPD) DESIGNATION AND EUROPEAN MEDICINES AGENCY ORPHAN MEDICINAL PRODUCT DESIGNATION (OMPD) FOR NB4168 FOR THE TREATMENT OF ATAXIA TELANGIECTASIA (A-T)
Reuters · 07/13 12:32
Weekly Report: what happened at NAGE last week (0706-0710)?
Weekly Report · 07/13 09:19
More
Webull provides a variety of real-time NAGE stock news. You can receive the latest news about Niagen Bioscience, Inc through multiple platforms. This information may help you make smarter investment decisions.
About NAGE
Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.